Intra-Cellular Therapies Inc (ITCI) Director Christopher D. Alafi Acquires 100,000 Shares

Intra-Cellular Therapies Inc (NASDAQ:ITCI) Director Christopher D. Alafi acquired 100,000 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were bought at an average price of $12.56 per share, for a total transaction of $1,256,000.00. Following the acquisition, the director now directly owns 750,106 shares of the company’s stock, valued at approximately $9,421,331.36. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of NASDAQ ITCI traded down $0.01 during trading on Thursday, hitting $12.35. 12,259 shares of the company traded hands, compared to its average volume of 325,503. Intra-Cellular Therapies Inc has a fifty-two week low of $10.21 and a fifty-two week high of $23.64. The firm has a market capitalization of $645.97 million, a P/E ratio of -4.32 and a beta of 1.39. The company has a current ratio of 9.59, a quick ratio of 9.59 and a debt-to-equity ratio of 0.07.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.27. Equities research analysts forecast that Intra-Cellular Therapies Inc will post -3.99 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc raised its holdings in shares of Intra-Cellular Therapies by 1.8% in the 3rd quarter. Vanguard Group Inc now owns 3,943,792 shares of the biopharmaceutical company’s stock worth $85,580,000 after acquiring an additional 69,950 shares during the last quarter. Citigroup Inc. raised its holdings in shares of Intra-Cellular Therapies by 19.7% in the 4th quarter. Citigroup Inc. now owns 22,585 shares of the biopharmaceutical company’s stock worth $257,000 after acquiring an additional 3,719 shares during the last quarter. Samlyn Capital LLC raised its holdings in shares of Intra-Cellular Therapies by 64.2% in the 4th quarter. Samlyn Capital LLC now owns 1,266,138 shares of the biopharmaceutical company’s stock worth $14,421,000 after acquiring an additional 494,918 shares during the last quarter. Norges Bank acquired a new stake in shares of Intra-Cellular Therapies in the 4th quarter worth about $3,759,000. Finally, Vanguard Group Inc. raised its holdings in shares of Intra-Cellular Therapies by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 3,943,792 shares of the biopharmaceutical company’s stock worth $85,580,000 after acquiring an additional 69,950 shares during the last quarter. Institutional investors own 69.34% of the company’s stock.

Several equities analysts have recently weighed in on the stock. BidaskClub upgraded shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Friday, April 26th. Cantor Fitzgerald reiterated a “buy” rating and set a $26.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, April 15th. Finally, ValuEngine upgraded shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Friday, March 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Intra-Cellular Therapies currently has an average rating of “Hold” and an average target price of $27.00.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2019/05/16/intra-cellular-therapies-inc-itci-director-christopher-d-alafi-acquires-100000-shares.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

Featured Story: Cost of Equity

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.